Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Small Cell Lung Carcinoma 1 Rectal Diseases 1 Pancreatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms by Site 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Gallbladder Neoplasms 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Colonic Diseases 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 126 Carboplatin 108 Pemetrexed 76 Paclitaxel 76 Cisplatin 73 Nivolumab 56 Docetaxel 53 Erlotinib Hydrochloride 50 Gemcitabine 49 Radiotherapy 48 Bevacizumab 32 osimertinib 31 Cetuximab 29 atezolizumab 25 Cyclophosphamide 25 durvalumab 24 130-nm albumin-bound paclitaxel 22 Oxaliplatin 19 Fluorouracil 18 Taxes 17 Radiosurgery 17 fludarabine 16 Magnetic Resonance Spectroscopy 16 Gefitinib 16 Ipilimumab 15 Vinorelbine 14 Leucovorin 14 Albumin-Bound Paclitaxel 14 Vorinostat 13 Radiation 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma, Non-Small-Cell Lung × guadecitabine × Clear all

NCT02998567 2026-05-12

HyPeR

Royal Marsden NHS Foundation Trust

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡